Clinical Trial Update: Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

This Phase 2 trial examines neoadjuvant atezolizumab followed by maintenance therapy for stage III non-small cell lung cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Fundación GECP | Conditions: Non Small Cell Lung Cancer, Stage IIIA Lung Cancer | Phase 2 | Status: RECRUITING